Dr. Marino Labinaz is a Cardiologist and Director of the Cardiac Fellowship Program at the University of Ottawa Heart Institute. Also, he is Professor of Medicine (Cardiology) at the University of Ottawa.
Dr. Labinaz earned his undergraduate degree and did his medical training at Queen’s University in Kingston, Ontario, followed by a three-year residency in Internal Medicine at the University of Western Ontario in London. Following training in Cardiology, he completed a two-year interventional fellowship at Duke University Medical Center in Durham, North Carolina, after which, in 1994, he returned to the Heart Institute as a full-time member of the Division of Cardiology.
Dr. Labinaz is involved in all aspects of interventional cardiology, including establishing and maintaining programs in intravascular ultrasound, percutaneous closure of atrial septal defects, patent foramen ovales and perivalvular leaks. He established a stand-alone interventional program in Thunder Bay, Ontario, and served as its Medical Director for two years. He and Dr. Marc Ruel created a new program for percutaneous aortic valve implantation at the Heart Institute. Dr. Labinaz was involved in developing STEMI. He has chaired a Cardiac Care Network panel on the Utility of Primary Angioplasty for Acute Myocardial Infarction for Ontario.
He has served as the site principal investigator in over 30 clinical trials and has been a contributing co-investigator in another 30 clinical trials. Dr. Labinaz has also served on the Steering Committee of several international multicentre trials. He has received peer-reviewed funding from the Heart and Stroke Foundation and has served as co-principal investigator on a number of grants from the Canadian Institutes of Health Research.
Dr. Labinaz has published over 185 research publications, presentations, book chapters and reviews.
Dr. Labinaz’s research interests include patient outcomes following percutaneous coronary intervention, outcome measures of patients with acute ST elevation myocardial infarction and other acute coronary syndromes.
In collaboration with Dr. Edward O’Brien, Dr. Labinaz has developed a novel drug-delivery catheter and was granted a patent for this innovation in 2003.
- Ruchin PE, Labinaz M. Which heparin and how much? Curr Cardiol Rep 2008 Jul;10(4):312-318. PMID: 18611366 (PubMed in process).
- McLellan CS, Ghali WA, Labinaz M, Davis RB, Galbraith PD, Southern DA, Shrive FM, Knudtson ML; Alberta Provincial Project for Outcomes Assessment in Coronary Heart Disease (APPROACH) investigators. Association between completeness of percutaneous coronary revascularization and postprocedure outcomes. Am Heart J 2005 Oct;150(4):800-806. PMID: 16209985 (PubMed in process).
- Dupuis JY, Labinaz M. Noncardiac surgery in patients with coronary artery stent: what should the anesthesiologist know?/La chirurgie non cardiaque chez des patients porteurs d'une endoprothèse coronaire: que devraient savoir les anesthesiologistes? Can J Anesth 2005 Apr;52(4):356-361. No abstract available. PMID: 15814748 (PubMed in process).
- Mehta SR, Steg PG, Granger CB, Bassand JP, Faxon DP, Weitz JI, Afzal R, Rush B, Peters RJ, Natarajan MK, Velianou JL, Goodhart DM, Labinaz M, Tanguay JF, Fox KA, Yusuf S; ASPIRE investigators. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: arixtra study in percutaneous coronary intervention: a randomized evaluation (ASPIRE) pilot trial. Circulation 2005 Mar 22;111(11):1390-1397. PMID: 15781750 (PubMed in process).
PAPERS IN REFEREED JOURNALS
- Le May MR, Wells GA, Labinaz M, Davies RF, Turek M, Leddy D, Maloney J, McKibbin T, Quinn B, Beanlands RS, Glover C, Marquis JF, O'Brien ER, Williams WL, Higginson LA. Combined Angioplasty and Pharmacological Intervention Versus Thrombolysis Alone in Acute Myocardial Infarction (CAPITAL AMI study). J Am Coll Cardiol. 2005 Aug 2;46(3):417-24. PMID: 16053952 [PubMed - indexed for MEDLINE]
- Le May M, Kurdi M, Labinaz M, Glover C, So D, Ryan S, Davies R. Safety of Coronary Stenting with Eptifibatide and Ultra-low-dose Heparin. Am J Cardiol. 2005 Mar 1;95(5):630-2. PMID: 15721106 [PubMed - indexed for MEDLINE]